Medroxyprogesterone in Treating Patients With Endometrioid Adenocarcinoma of the Uterine Corpus

Summary

This phase II trial is studying how well medroxyprogesterone works in treating patients with endometrioid adenocarcinoma (cancer) of the uterine corpus (the body of the uterus, not including the cervix). Hormone therapy using medroxyprogesterone may be effective in treating endometrioid cancer.

Timeline

Start

2004-04

Primary completion

2010-09

Completion

—

Outcome

Missed primary endpoint

registry PR Negative (<=0.2) vs PR Positive (>0.2); p = 0.701; Fisher Exact NCT00064025 ↗

Drugs

Indications